Table 4.
Mean and standard deviation of MG-ADL and QMG scores in Ocular signs at the beginning and at the end of each cycle of therapy with Efgartigimod.
| Ocular signs in MG-ADL assessment in all patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° Cycle | 2° Cycle | 3° Cycle | p value* | ||||||||
| MG-ADL | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 2.22 | 1.56 | 2.00 | 1.11 | 1.80 | 1.40 | 0.28 | 0.044 | 0.34 | 0.036 | 0.031 |
| SD | 1.39 | 1.51 | 1.73 | 1.16 | 1.44 | 1.56 | |||||
| Ocular signs in QMG assessment in all patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° Cycle | 2° Cycle | 3° Cycle | p value* | ||||||||
| QMG | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 2.88 | 1.55 | 2.44 | 2.00 | 2.40 | 1.00 | 0.050 | 0.16 | 0.10 | 0.19 | 0.01 |
| SD | 1.87 | 1.23 | 2.00 | 1.78 | 1.23 | 1.32 | |||||
* Repeated measures ANOVA with Post Hoc analysis using Bonferroni method.